1. cis-cyclopropylamines as mechanism-based inhibitors of monoamine oxidases
   Thomas Malcomson et al, 2015, FEBS J CrossRef
2. DNA and Histone Methylation in Prostate Cancer
   Kexin Xu, 2017 CrossRef
3. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer
   Woo Sun et al, 2017, IJMS CrossRef
4. Iron mediated toxicity and programmed cell death: A review and a re-examination of existing paradigms
   Rawan Eid et al, 2017, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research CrossRef
5. Site-specific expression of amine oxidases in breast cancer metastases
   Yoon Jin Cha et al, 2018, Tumour Biol. CrossRef
6. Optimization of 5-Arylidene Barbiturates as Potent, Selective, Reversible LSD1 Inhibitors for the Treatment of Acute Promyelocytic Leukemia
   Siyuan Xu et al, 2018, Bioorganic & Medicinal Chemistry CrossRef
7. Cell Size-Based Decision-Making of a Viral Gene Circuit
   Kathrin Bohn-Wippert et al, 2018, Cell Reports CrossRef
8. Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors
   Shuai Wang et al, 2019, European Journal of Medicinal Chemistry CrossRef
9. Lysine-specific demethylase 1 inhibitor rescues the osteogenic ability of mesenchymal stem cells under osteoporotic conditions by modulating H3K4 methylation
   Longwei Lv et al, 2016, Bone Res CrossRef
10. MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells
    Yi-Cheng Lin et al, 2017, Sci Rep CrossRef
11. The Up-Regulation of Oxidative Stress as a Potential Mechanism of Novel MAO-B Inhibitors for Glioblastoma Treatment
    Guya Diletta Marconi et al, 2019, Molecules CrossRef
12. Monoamine oxidase A and B substrates: probing the pathway for drug development
    Sarah Chajkowski-Scarry et al, 2014, Future Medicinal Chemistry CrossRef
13. Histone Posttranslational Modifications and Chromatin Remodelers in Prostate Cancer
    Filipa Quintela Vieira et al, 2016 CrossRef
14. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy
    Yi-Chao Zheng et al, 2016, Epigenomics CrossRef
15. Epigenetic modulators as therapeutic targets in prostate cancer
    Inês Graça et al, 2016, Clin Epigenet CrossRef
16. Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors
    Shuai Wang et al, 2017, European Journal of Medicinal Chemistry CrossRef
17. Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors
    Liying Ma et al, 2020, Acta Pharmaceutica Sinica B CrossRef
18. Histone Demethylase LSD1 Regulates Kidney Cancer Progression by Modulating Androgen Receptor Activity
    Kyoung-Hwa Lee et al, 2020, IJMS CrossRef
19. Testicular and prostate cancers
    Eva Tvrdá, 2021 CrossRef
20. Monoamine Oxidase A (MAO-A): A Therapeutic Target in Lung Cancer
    Chandreyee Datta et al, 2021 CrossRef
21. Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development
    Reem Aljanabi et al, 2021, Molecules CrossRef
22. Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent
    Ritu Ojha et al, 2021, J. Med. Chem. CrossRef
23. Programmed biomolecule delivery orchestrate bone tissue regeneration via MSC recruitment and epigenetic modulation
    Zhuqing Wan et al, 2022, Chemical Engineering Journal CrossRef
24. A Comparison of Network-Based Methods for Drug Repurposing along with an Application to Human Complex Diseases
    Giulia Fiscon et al, 2022, IJMS CrossRef
25. The paradigm of drug resistance in cancer: an epigenetic perspective.
    Swagata Adhikari et al, 2022, Biosci Rep CrossRef
26. New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity
    Sara Silva et al, 2022, IJMS CrossRef
27. Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?
    Premysl Vlcek et al, 2023, J Psychopharmacol CrossRef
28. Unveiling the Molecular Landscape of FOXA1 Mutant Prostate Cancer: Insights and Prospects for Targeted Therapeutic Strategies
    Kyung Won Hwang et al, 2023, IJMS CrossRef
29. Research progress of LSD1-based dual-target agents for cancer therapy
    Xiaojuan Yang, 2024, Bioorganic & Medicinal Chemistry CrossRef
30. DAS-DDI: A dual-view framework with drug association and drug structure for drug-drug interaction prediction
    Dongjiang Niu et al, 2024, Journal of Biomedical Informatics CrossRef
31. New Insight into Breast Cancer Cells Involving Drug Combinations for Dopamine and Serotonin Receptors
    Bárbara Costa et al, 2021, Applied Sciences CrossRef
32. HSP90/LSD1 Dual Inhibitors against Prostate Cancer as well as Patient-Derived Colorectal Organoids
    Di-Wei Tang et al, 2024, European Journal of Medicinal Chemistry CrossRef
33. THE EFFECT OF PARGILINE, SPERMINE AND THEIR COMBINATIONS ON ANDROGEN-DEPENDENT AND ANDROGEN-INDEPENDENT HUMAN PROSTATE CANCER CELLS in vitro
    Yu.V. Yanish et al, 2024, Oncology CrossRef
34. The highs and lows of monoamine oxidase as molecular target in cancer: an updated review
    Iasmina M. Hâncu et al, 2024, Mol Cell Biochem CrossRef
35. Targeting MAO-B with Small-Molecule Inhibitors: A Decade of Advances in Anticancer Research (2012–2024)
    Iyman Alsaad et al, 2024, Molecules CrossRef